Psychoneuroendocrinimmunodermatology: Pathophysiological Mechanisms of Stress in Cutaneous Disease

Psychocutaneous Medicine

Volumn , Issue , 2003, Pages 65-95

  Zane, Lee Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42649107628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203911877-9     Document Type: Chapter

References (145)

1. Al’Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol 1994; 130:199-203.
2. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom 2001; 70:118-136.
3. Selye H. The general adaptation syndrome and the disease of adaptation. J Clin Endocrinol 1946; 6:117-230.
4. Panconesi E, Hautmann G. Psychophysiology of stress in dermatology. The psychobiologic pattern of psychosomatics. Dermatol Clin 1996; 14:399-421.
5. Spiegel D. Healing words: emotional expression and disease outcome. JAMA 1999; 281:1328-1329.
6. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-1362.
7. Agarwal SK, Marshall GD Jr. Stress effects on immunity and its application to clinical immunology. Clin Exp Allergy 2001; 31:25-31.
8. Dhabhar FS. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann NY Acad Sci 2000; 917:876-893.
9. Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001; 169:429-435.
10. Dhabhar FS, McEwen BS. Stress-induced enhancement of antigen-specific cell-mediated immunity. J Immunol 1996; 156:2608-2615.
11. Dhabhar FS, Miller AH, McEwen BS, Spencer RL. Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. J Immunol 1996; 157:1638-1644.
12. Dhabhar FS, Satoskar AR, Bluethmann H, David JR, McEwen BS. Stressinduced enhancement of skin immune function: a role for gamma interferon. Proc Natl Acad Sci USA 2000; 97:2846-2851.
13. Elenkov IJ, Chrousos GP. Stress, cytokine patterns and susceptibility to disease. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:583-595.
14. Wu CY, Wang K, McDyer JF, Seder RA. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998; 161:2723-2730.
15. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O’Shea JJ. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 2000; 164:1768-1774.
16. Ramierz F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a TH2 cytokine response by CD4þ T cells in vitro. J Immunol 1996; 156:2406-2412.
17. Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES. Stimulation of betaadrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J Neuroimmunol 1998; 88:57-61.
18. Elenkov IJ, Chrousos GP. Stress hormones, Th1/Th2 patterns, pro/antiinflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999; 10:359-368.
19. Wick G, Hu Y, Schwarz S, Kroemer G. Immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune diseases. Endocr Rev 1993; 14:539-563.
20. Lechner O, Hu Y, Jafarian-Tehrani M, Dietrich H, Schwarz S, Herold M, Haour F, Wick G. Disturbed immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in murine lupus. Brain Behav Immun 1996; 10:337-350.
21. Jafarian-Tehrani M, Sternberg EM. Animal models of neuroimmune interactions in inflammatory diseases. J Neuroimmunol 1999; 100:13-20.
22. Misiewicz B, Poltorak M, Raybourne RB, Gomez M, Listwak S, Sternberg EM. Intracerebroventricular transplantation of embryonic neuronal tissue from inflammatory resistant into inflammatory susceptible rats suppresses specific components of inflammation. Exp Neurol 1997; 146:305-314.
23. Buske-Kirschbaum A, Jobst S, Psych D, Wustmans A, Kirschbaum C, Rauh W, Hellhammer D. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis. Psychosom Med 1997; 59:419-426.
24. Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 1999; 26:277-281.
25. Gutierrez MA, Garcia ME, Rodriguez JA, Rivero S, Jacobelli S. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus 1998; 7:404-408.
26. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, Tzioufas AG, Moutsopoulos HM. Hypofunction of the stress axis in Sjögren’s syndrome. J Rheumatol 1998; 25:1508-1514.
27. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitaryadrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37:1583-1592.
28. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73:1224-1234.
29. Sternberg EM. Neural-immune interactions in health and disease. J Clin 1997; Invest 100:2641-2647.
30. Kellendonk C, Tronche F, Reichardt HM, Schutz G. Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol 1999; 69:253-259.
31. Franchimont D, Louis E, Dupont P, Vrindts-Gevaert Y, Dewe W, Chrousos G, Geenen V, Belaiche J. Decreased corticosensitivity in quiescent Crohn’s disease: an ex vivo study using whole blood cell cultures. Dig Dis Sci 1999; 44:1208-1215.
32. Denda M, Tsuchiya T, Hosoi J, Koyama J. Immobilization-induced and crowded environment-induced stress delay barrier recovery in murine skin. Br J Dermatol 1998; 138:780-785.
33. Denda M, Tsuchiya T, Elias PM, Feingold KR. Stress alters cutaneous permeability barrier homeostasis. Am J Physiol Regul Integr Comp Physiol 2000; 278:R367-372.
34. Garg A, Chren MM, Sands LP, Matsui MS, Marenus KD, Feingold KR, Elias PM. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol 2001; 137:53-59.
35. Malarkey WB, Pearl DK, Demers LM, Kiecolt-Glaser JK, Glaser R. Influence of academic stress and season on 24-hour mean concentrations of ACTH, cortisol, and beta-endorphin. Psychoneuroendocrinology 1995; 20:499-508.
36. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998; 7:81-96.
37. Lawson SN. Peptides and cutaneous polymodal nociceptor neurones. Prog Brain Res 1996; 113:369-385.
38. Schulze E, Witt M, Fink T, Hofer A, Funk RH. Immunohistochemical detection of human skin nerve fibers. Acta Histochem 1997; 99:301-309.
39. Reilly DM, Ferdinando D, Johnston C, Shaw C, Buchanan KD, Green MR. The epidermal nerve fibre network: characterization of nerve fibres in human skin by confocal microscopy and assessment of racial variations. Br J Dermatol 1997; 137:163-170.
40. Bost KL, Breeding SA, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg Immunol 1992; 4:105-112.
41. Vedder H, Affolter HU, Otten U. Nerve growth factor (NGF) regulates tachykinin gene expression and biosynthesis in rat sensory neurons during early postnatal development. Neuropeptides 1993; 24:351-357.
42. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150:4478-4485.
43. Bowden JJ, Baluk P, Lefevre PM, Vigna SR, McDonald DM. Substance P (NK1) receptor immunoreactivity on endothelial cells of the rat tracheal mucosa. Am J Physiol 1996; 270:L404-414.
44. Quinlan KL, Naik SM, Cannon G, Armstrong CA, Bunnett NW, Ansel JC, Caughman SW. Substance P activates coincident NF-AT- and NF-kappa Bdependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 1999; 163:5656-5665.
45. Quinlan KL, Song IS, Bunnett NW, Letran E, Steinhoff M, Harten B, Olerud JE, Armstrong CA, Wright Caughman S, Ansel JC. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998; 275:C1580-1590.
46. Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnett NW, Armstrong CA, Caughman SW, Ansel JC. VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol 1999; 162:1656-1661.
47. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol 1993; 151:2484-2496.
48. Calvo CF, Chavanel G, Senik A. Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992; 148:3498-3504.
49. Santoni G, Perfumi MC, Spreghini E, Romagnoli S, Piccoli M. Neurokinin type-1 receptor antagonist inhibits enhancement of T cell functions by substance P in normal and neuromanipulated capsaicin-treated rats. J Neuroimmunol 1999; 93:15-25.
50. Pascual DW, Bost KL, Xu-Amano J, Kiyono H, McGhee JR. The cytokinelike action of substance P upon B cell differentiation. Reg Immunol 1992; 4:100-104.
51. Braun A, Wiebe P, Pfeufer A, Gessner R, Renz H. Differential modulation of human immunoglobulin isotype production by the neuropeptides substance P, NKA and NKB. J Neuroimmunol 1999; 97:43-50.
52. Burbach GJ, Kim KH, Zivony AS, Kim A, Aranda J, Wright S, Naik SM, Caughman SW, Ansel JC, Armstrong CA. The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001; 117:1075-1082.
53. Song IS, Bunnett NW, Olerud JE, Harten B, Steinhoff M, Brown JR, Sung KJ, Armstrong CA, Ansel JC. Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK-2R). Exp Dermatol 2000; 9:42-52.
54. Kiss M, Kemeny L, Gyulai R, Michel G, Husz S, Kovacs R, Dobozy A, Ruzicka T. Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. Inflammation 1999; 23:557-567.
55. Rabier MJ, Farber EM, Wilkinson DI. Neuropeptides modulate leukotriene B4 mitogenicity toward cultured human keratinocytes. J Invest Dermatol 1993; 100:132-136.
56. Parenti A, Amerini S, Ledda F, Maggi CA, Ziche M. The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunyn Schmiedebergs Arch Pharmacol 1996; 353:475-481.
57. Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J Dermatol Sci 1997; 15:201-206.
58. Wiedermann CJ, Auer B, Sitte B, Reinisch N, Schratzberger P, Kahler CM. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol 1996; 298:335-338.
59. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-824.
60. Tsuchiya T, Kishimoto J, Granstein RD, Nakayama Y. Quantitative analysis of cutaneous calcitonin gene-related peptide content in response to acute cutaneous mechanical or thermal stimuli and immobilization-induced stress in rats. Neuropeptides 1996; 30:149-157.
61. Chan J, Smoller BR, Raychauduri SP, Jiang WY, Farber EM. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997; 289:611-616.
62. Carucci JA, Ignatius R, Wei Y, Cypess AM, Schaer DA, Pope M, Steinman RM, Mojsov S. Calcitonin gene-related peptide decreases expression of HLADR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 2000; 164:3494-3499.
63. Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, Granstein RD, Trinchieri G, Rook AH. Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997; 108:43-48.
64. Toyoda M, Luo Y, Makino T, Matsui C, Morohashi M. Calcitonin generelated peptide upregulates melanogenesis and enhances melanocyte dendricity via induction of keratinocyte-derived melanotrophic factors. J Invest Dermatol Symp Proc 1999; 4:116-125.
65. Seike M, Ikeda M, Morimoto A, Matsumoto M, Kodama H. Increased synthesis of calcitonin gene-related peptide stimulates keratinocyte proliferation in murine UVB-irradiated skin. J Dermatol Sci 2002; 28:135-143.
66. Kakurai M, Fujita N, Murata S, Furukawa Y, Demitsu T, Nakagawa H. Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors. J Invest Dermatol 2001; 116:743-749.
67. Gonzalez C, Barroso C, Martin C, Gulbenkian S, Estrada C. Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries. J Cereb Blood Flow Metab 1997; 17:977-984.
68. Jiang WY, Raychaudhuri SP, Farber EM. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 1998; 37:572-574.
69. Waschek JA. Vasoactive intestinal peptide: an important trophic factor and developmental regulator? Dev Neurosci 1995; 17:1-7.
70. Fristad I, Jacobsen EB, Kvinnsland IH. Coexpression of vasoactive intestinal polypeptide and substance P in reinnervating pulpal nerves and in trigeminal ganglion neurones after axotomy of the inferior alveolar nerve in the rat. Arch Oral Biol 1998; 43:183-189.
71. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990; 122:745-750.
72. Church MK, el-Lati S, Caulfield JP. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991; 94:310-318.
73. Redondo P, Garcia-Foncillas J, Okroujnov I, Bandres E. Alpha-MSH regulates interleukin-10 expression by human keratinocytes. Arch Dermatol Res 1998; 290:425-428.
74. Hedley SJ, Murray A, Sisley K, Ghanem G, Morandini R, Gawkrodger DJ, Mac Neil S. Alpha-melanocyte stimulating hormone can reduce T-cell interaction with melanoma cells in vitro. Melanoma Res 2000; 10:323-330.
75. Etemad-Moghadam B, Chen H, Yin P, Aziz N, Hedley ML. Inhibition of NFkappaB activity by plasmid expressed alphaMSH peptide. J Neuroimmunol 2002; 125:23-29.
76. Ichiyama T, Okada K, Campbell IL, Furukawa S, Lipton JM. NF-kappaB activation is inhibited in human pulmonary epithelial cells transfected with alpha-melanocyte-stimulating hormone vector. Peptides 2000; 21:1473-1477.
77. Kalden DH, Scholzen T, Brzoska T, Luger TA. Mechanisms of the antiinflammatory effects of alpha-MSH. Role of transcription factor NF-kappa B and adhesion molecule expression. Ann NY Acad Sci 1999; 885:254-261.
78. Luger TA, Scholzen T, Brzoska T, Becher E, Slominski A, Paus R. Cutaneous immunomodulation and coordination of skin stress responses by alphamelanocyte-stimulating hormone. Ann NY Acad Sci 1998; 840:381-394.
79. Biondi M, Zannino LG. Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Psychother Psychosom 1997; 66:3-26.
80. Broadbent DE, Broadbent MH, Phillpotts RJ, Wallace J. Some further studies on the prediction of experimental colds in volunteers by psychological factors. J Psychosom Res 1984; 28:511-523.
81. Konstantinos AP, Sheridan JF. Stress and influenza viral infection: modulation of proinflammatory cytokine responses in the lung. Respir Physiol 2001; 128:71-77.
82. Dibble SL, Swanson JM. Gender differences for the predictors of depression in young adults with genital herpes. Public Health Nurs 2000; 17:187-194.
83. Buske-Kirschbaum A, Geiben A, Wermke C, Pirke KM, Hellhammer D. Preliminary evidence for herpes labialis recurrence following experimentally induced disgust. Psychother Psychosom 2001; 70:86-91.
84. Levenson JL, Hamer RM, Myers T, Hart RP, Kaplowitz LG. Psychological factors predict symptoms of severe recurrent genital herpes infection. J Psychosom Res 1987; 31:153-159.
85. Cassidy L, Meadows J, Catalan J, Barton S. Are reported stress and coping style associated with frequent recurrence of genital herpes? Genitourin Med 1997; 73:263-266.
86. Cohen F, Kemeny ME, Kearney KA, Zegans LS, Neuhaus JM, Conant MA. Persistent stress as a predictor of genital herpes recurrence. Arch Intern Med 1999; 159:2430-2436.
87. Rand KH, Hoon EF, Massey JK, Johnson JH. Daily stress and recurrence of genital herpes simplex. Arch Intern Med 1990; 150:1889-1893.
88. Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections. Herpetic Eye Disease Study Group. Arch Ophthalmol 2000; 118:1617-1625.
89. Hoon EF, Hoon PW, Rand KH, Johnson J, Hall NR, Edwards NB. A psycho-behavioral model of genital herpes recurrence. J Psychosom Res 1991; 35:25-36.
90. Longo D, Koehn K. Psychosocial factors and recurrent genital herpes: a review of prediction and psychiatric treatment studies. Int J Psychiatry Med 1993; 23:99-117.
91. Green J, Kocsis A. Psychological factors in recurrent genital herpes. Genitourin Med 1997; 73:253-258.
92. McKenna DB, Neill WA, Norval M. Herpes simplex virus-specific immune responses in subjects with frequent and infrequent orofacial recrudescences. Br J Dermatol 2001; 144:459-464.
93. Sainz B, Loutsch JM, Marquart ME, Hill JM. Stress-associated immunomodulation and herpes simplex virus infections. Med Hypotheses 2001; 56:348-356.
94. Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol 1999; 162:3527-3533.
95. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000; 66:348-352.
96. Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 41 Part 2002; 2:157-174.
97. Nickoloff BJ, Schroder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, Morhenn VB, Rosenberg EW, Schon MP, Holick MF. Is psoriasis a T-cell disease? Exp Dermatol 2000; 9:359-375.
98. Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry, and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 1986; 14:305-311.
99. Raychaudhuri SP, Farber EM. Are sensory nerves essential for the development of psoriatic lesions? J Am Acad Dermatol 1993; 28:488-489.
100. Raychaudhuri SP, Jiang WY, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 1998; 78:84-86.
101. Raychaudhuri SP, Jiang WY, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. Br J Dermatol 2000; 143:198-200.
102. Aloe L, Alleva E, Fiore M. Stress and nerve growth factor. Findings in animal models and humans. Pharmacol Biochem Behav 2002; 73:159-166.
103. Wilkinson DI, Theeuwes MJ, Farber EM. Nerve growth factor increases the mitogenicity of certain growth factors for cultured human keratinocytes: a comparison with epidermal growth factor. Exp Dermatol 1994; 3:239-245.
104. Aloe L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977; 133:358-366.
105. Aloe L. Nerve growth factor and neuroimmune responses: basic and clinical observations. Arch Physiol Biochem 2001; 109:354-356.
106. Thorpe LW, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on the expression of interleukin-2 receptors on cultured human lymphocytes. Ann NY Acad Sci 1987; 496:310-311.
107. Lambiase A, Bracci-Laudiero L, Bonini S, Starace G, D’Elios MM, De Carli M, Aloe L. Human CD4þ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. J Allergy Clin Immunol 1997; 100:408-414.
108. Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999; 79:9-11.
109. Raychaudhuri SP, Farber EM, Raychaudhuri SK. Role of nerve growth factor in RANTES expression by keratinocytes. Acta Derm Venereol 2000; 80:247-250.
110. Richter J, Andersson R, Edvinsson L, Gullberg U. Calcitonin gene-related peptide (CGRP) activates human neutrophils—inhibition by chemotactic peptide antagonist BOC-MLP. Immunology 1992; 77:416-421.
111. Sung CP, Arleth AJ, Aiyar N, Bhatnagar PK, Lysko PG, Feuerstein G. CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. Peptides 1992; 13:429-434.
112. Pincelli C, Haake AR, Benassi L, Grassilli E, Magnoni C, Ottani D, Polakowska R, Franceschi C, Giannetti A. Autocrine nerve growth factor protects human keratinocytes from apoptosis through its high affinity receptor (TRK): a role for BCL-2. J Invest Dermatol 1997; 109:757-764.
113. Hong KW, Yoo SE, Yu SS, Lee JY, Rhim BY. Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am J Physiol 1996; 270:H317-323.
114. Pearce FL, Thompson HL. Some characteristics of histamine secretion from rat peritoneal mast cells stimulated with nerve growth factor. J Physiol 1986; 372:379-393.
115. Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol 1996; 81:68-73.
116. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 1986; 87:533-536.
117. Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 1999; 68:221-225.
118. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146:458-465.
119. King RM, Wilson GV. Use of a diary technique to investigate psychosomatic relations in atopic dermatitis. J Psychosom Res 1991; 35:697-706.
120. Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom 2001; 70:6-16.
121. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105:860-876.
122. Kagi MK, Wuthrich B, Montano E, Barandun J, Blaser K, Walker C. Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol 1994; 103:332-340.
123. Heubeck B, Schonberger A, Hornstein OP. [Are shifts in circadian cortisol rhythm an endocrine symptom of atopic eczema?]. Hautarzt 1988; 39:12-17.
124. Rupprecht M, Hornstein OP, Schluter D, Schafers HJ, Koch HU, Beck G, Rupprecht R. Cortisol, corticotropin, and beta-endorphin responses to corticotropin-releasing hormone in patients with atopic eczema. Psychoneuroendocrinology 1995; 20:543-551.
125. Rupprecht M, Rupprecht R, Kornhuber J, Wodarz N, Koch HU, Riederer P, Hornstein OP. Elevated glucocorticoid receptor concentrations before and after glucocorticoid therapy in peripheral mononuclear leukocytes of patients with atopic dermatitis. Dermatologica 1991; 183:100-105.
126. Schallreuter KU, Pittelkow MR, Swanson NN, Beazley WD, Korner C, Ehrke C, Buttner G. Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. Arch Dermatol Res 1997; 289:663-666.
127. Delgado M, Fernandez-Alfonso MS, Fuentes A. Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line. Arch Dermatol Res 2002; 294:190-197.
128. Chan SC, Brown MA, Willcox TM, Li SH, Stevens SR, Tara D, Hanifin JM. Abnormal IL-4 gene expression by atopic dermatitis T lymphocytes is reflected in altered nuclear protein interactions with IL-4 transcriptional regulatory element. J Invest Dermatol 1996; 106:1131-1136.
129. Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993; 100:681-684.
130. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SK. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. Biochem Pharmacol 1997; 53:1055-1060.
131. Kanda N, Watanabe S. Intracellular 30; 50-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis. J Invest Dermatol 2001; 116:3-11.
132. Yoshida N, Shimizu Y, Kitaichi K, Hiramatsu K, Takeuchi M, Ito Y, Kume H, Yamaki K, Suzuki R, Shibata E, Hasegawa T, Takagi K. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin Exp Immunol 2001; 126:384-389.
133. Li Y, Simons FE, HayGlass KT. Environmental antigen-induced IL-13 responses are elevated among subjects with allergic rhinitis, are independent of IL-4, and are inhibited by endogenous IFN-gamma synthesis. J Immunol 1998; 161:7007-7014.
134. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire.’ Int Arch Allergy Immunol 2001; 124:326-331.
135. Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M. Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. Arch Dermatol Res 1997; 289:125-131.
136. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90:613-622.
137. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci 1997; 17:8003-8008.
138. Ostlere LS, Cowen T, Rustin MH. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995; 20:462-467.
139. Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch 1998; 432:363-370.
140. Darsow U, Ring J. Neuroimmune interactions in the skin. Curr Opin Allergy Clin Immunol 2001; 1:435-439.
141. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999; 13:225-239.
142. Kang H, Byun DG, Kim JW. Effects of substance P and vasoactive intestinal peptide on interferon-gamma and interleukin-4 production in severe atopic dermatitis. Ann Allergy Asthma Immunol 2000; 85:227-232.
143. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002; 147:71-79.
144. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23.
145. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.